Analysts Offer Insights on Healthcare Companies: SAGE Therapeutics (SAGE) and Biohaven Pharmaceutical Holding Co Ltd (BHVN)


Analysts have been eager to weigh in on the Healthcare sector with new ratings on SAGE Therapeutics (SAGE) and Biohaven Pharmaceutical Holding Co Ltd (BHVN).

SAGE Therapeutics (SAGE)

In a report released today, Marc Goodman from Leerink Partners initiated coverage with a Sell rating on SAGE Therapeutics and a price target of $80. The company’s shares closed yesterday at $108.05.

According to TipRanks.com, Goodman is a 3-star analyst with an average return of 1.8% and a 47.4% success rate. Goodman covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co Ltd, ACADIA Pharmaceuticals Inc, and Intra-Cellular Therapies.

Currently, the analyst consensus on SAGE Therapeutics is a Strong Buy with an average price target of $205.42.

See today’s analyst top recommended stocks >>

Biohaven Pharmaceutical Holding Co Ltd (BHVN)

In a report released today, Charles Duncan from Cantor Fitzgerald maintained a Buy rating on Biohaven Pharmaceutical Holding Co Ltd, with a price target of $55. The company’s shares closed yesterday at $33.68.

According to TipRanks.com, Duncan is a 1-star analyst with an average return of -2.0% and a 39.9% success rate. Duncan covers the Healthcare sector, focusing on stocks such as KalVista Pharmaceuticals Inc, ACADIA Pharmaceuticals Inc, and Corcept Therapeutics Inc.

Currently, the analyst consensus on Biohaven Pharmaceutical Holding Co Ltd is a Strong Buy with an average price target of $53, representing a 57.4% upside. In a report issued on November 12, Oppenheimer also initiated coverage with a Buy rating on the stock with a $63 price target.

.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts